Iambic Therapeutics, Inc. IAM
IPO
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 6.38M | 6.38M | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 6.38M | 6.38M | |||
| Cost of Revenue | 28.57M | 28.57M | |||
| Gross Profit | -22.20M | -22.20M | |||
| SG&A Expenses | 4.56M | 4.56M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 33.13M | 33.13M | |||
| Operating Income | -26.76M | -26.76M | |||
| Income Before Tax | -25.06M | -25.06M | |||
| Income Tax Expenses | 1.00K | 1.00K | |||
| Earnings from Continuing Operations | -25.06M | -25.06M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -25.06M | -25.06M | |||
| EBIT | -26.76M | -26.76M | |||
| EBITDA | -26.41M | -26.41M | |||
| EPS Basic | -1.12 | -1.12 | |||
| Normalized Basic EPS | -0.70 | -0.70 | |||
| EPS Diluted | -1.12 | -1.12 | |||
| Normalized Diluted EPS | -0.70 | -0.70 | |||
| Average Basic Shares Outstanding | 22.42M | 22.42M | |||
| Average Diluted Shares Outstanding | 22.42M | 22.42M | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||